Patient derived renal cell carcinoma xenografts exhibit distinct sensitivity patterns in response to antiangiogenic therapy and constitute a suitable tool for biomarker development

Systemic treatment is necessary for one third of patients with renal cell carcinoma. No valid biomarker is currently available to tailor personalized therapy. In this study we established a representative panel of patient derived xenograft (PDX) mouse models from patients with renal cell carcinomas...

Descripción completa

Detalles Bibliográficos
Autores principales: Schueler, Julia, Klingner, Kerstin, Bug, Daniel, Zoeller, Caren, Maier, Armin, Dong, Meng, Willecke, Kerstin, Peille, Anne-Lise, Steiner, Eva, Landesfeind, Manuel, Copland, John A., Siegers, Gabrielle M., Haferkamp, Axel, Boehm, Katharina, Tsaur, Igor, Schneider, Meike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089561/
https://www.ncbi.nlm.nih.gov/pubmed/30123419
http://dx.doi.org/10.18632/oncotarget.25697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6089561/
https://www.ncbi.nlm.nih.gov/pubmed/30123419
http://dx.doi.org/10.18632/oncotarget.25697

Ejemplares similares